Dostarlimab with docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6530]

  • Awaiting development
  • GID-TA11655
  • Expected publication date: TBC

Suggested remit: To appraise the clinical and cost effectiveness of Dostarlimab and docetaxel within its marketing authorisation for treating non-small-cell lung cancer